预约演示
更新于：2025-05-16
Loratadine
氯雷他定
更新于：2025-05-16
概要
基本信息
简介Claritin（氯雷他定）是一种常用于治疗花粉热和荨麻疹等过敏症的药物。 它属于第二代抗组胺药家族，口服。 虽然常见的副作用包括口干、嗜睡和头痛，但过敏反应、癫痫发作和肝脏问题等严重副作用很少见。 氯雷他定在怀孕期间通常被认为是安全的，但其在这一人群中的作用尚未得到很好的研究。 两岁以下的儿童不应服用这种药物。 氯雷他定于 1980 年获得专利，并于 1988 年首次上市。它被世界卫生组织列为基本药物，可作为仿制药使用。 在美国，它可以在柜台购买，是 2020 年最常用的处方药之一，有超过 900 万张处方。 |
药物类型 小分子化药 |
别名 Loratadine (JAN/USP/INN)、Loratadine Effervescent、Loratadine Hydrochloride + [56] |
作用方式 拮抗剂 |
作用机制 H1 receptor拮抗剂(组胺H1受体拮抗剂) |
非在研适应症 |
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1993-04-12), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C22H23ClN2O2 |
InChIKeyJCCNYMKQOSZNPW-UHFFFAOYSA-N |
CAS号79794-75-5 |
关联
80
项与 氯雷他定 相关的临床试验NCT06955741
A Phase 1, Randomized, Open-label, Parallel, Single-dose Study to Assess the Pharmacokinetics, Tolerability, and Absolute Bioavailability of Subcutaneous Administration of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Healthy Participants
ACTRN12624000019505
A Randomized, Open Label, Balanced, Two-Treatment, Two-Period, Two-Sequence, Single Dose, Two-Way Crossover, Bioequivalence Study of Loratadine 5mg Chewable Tablets of AFT Pharmaceuticals, Australia Compared with Children's Claratyne® Grape 5 mg Chewable Tablets in Healthy Human Adult Subjects Under Fasting Conditions.
CTRI/2024/12/077559
An Open Label Balanced Randomized Single Dose Two Treatment Three Sequence Three Period Partial Replicate Reference Scaled Average Oral Bioequivalence Study Comparing Loratadine 1 mg/mL Oral Liquid Solution 10 X 1 mg/mL Manufactured at S Kant Healthcare Ltd for Neo Health OTC Pty Ltd with Childrens Claratyne Loratadine 1 mg/mL Peach Flavour Oral Liquid Solution Bottle 10 X 1 mg/mL Aust R 44453) distributed by Bayer Australia Ltd in Healthy Adult Human Subjects Under Fasting Conditions - NIL
100 项与 氯雷他定 相关的临床结果
登录后查看更多信息
100 项与 氯雷他定 相关的转化医学
登录后查看更多信息
100 项与 氯雷他定 相关的专利（医药）
登录后查看更多信息
3,226
项与 氯雷他定 相关的文献（医药）2025-06-01MARINE POLLUTION BULLETIN
A robust method to quantify pharmaceuticals for the United Nations endorsed Global Estuaries Monitoring (GEM) Programme
Article
作者: Xu, Shaopeng ; Zhou, Guang-Jie ; Lai, Racliffe Weng Seng ; Chen, Chong ; Adedipe, Demilade T ; Luo, Qiong ; Brooks, Bryan W ; Leung, Kenneth Mei Yee ; Boxall, Alistair B A
Following human and animal consumption, pharmaceuticals often remain incompletely metabolized, entering aquatic ecosystems via sources like wastewater discharges, landfill leachates, and aquaculture farms, thereby eventually reaching the ocean through estuaries. This influx poses a significant threat to marine ecosystems. The Global Estuaries Monitoring (GEM) Programme, endorsed by the United Nations Decade of Ocean Science for Sustainable Development (2021-2030), aims to establish a standardized method for monitoring pharmaceuticals in the world's estuaries. This study was performed for simultaneously quantifying 65 pharmaceuticals in small-volume of water samples. The findings revealed that using 20 mL water yielded optimal recoveries between 60 % and 130 %. The influence of pH, salinity and sample matrix on the performance of the method was minimal. 45-50 pharmaceuticals remained stable over a seven-day storage period at both 4 °C and 25 °C. This cost-effective and user-friendly method paves the way for the GEM Programme to monitor pharmaceuticals in over 100 estuaries worldwide.
2025-06-01MARINE POLLUTION BULLETIN
Nontargeted screening of contaminants of emerging concern in the Nandu River Estuary
Article
作者: Liu, He ; Cao, Qingyang ; Yang, Jingjing ; Li, Yihao ; Shi, Liangliang ; Deng, Yu ; Ma, Yini ; Jia, Wenhao ; Huang, Kaibo
Contaminants of emerging concern (CECs) in estuaries have received increasing attention due to their potential environmental impacts. However, detailed analyses of the sources, transport mechanisms, and environmental consequences of these contaminants remain limited. This study applied non-target screening technology to comprehensively assess CECs in the Nandu River estuary. A total of 18,000 characteristic features were screened, revealing a greater number of hydrophobic features in seawater than in the estuary. Systematic classification identified 74, 195, and 48 compounds at Levels 1, 2, and 4 respectively, with primary classifications comprising pharmaceuticals (34 %), industrial materials (23 %), pesticides (18 %), and natural products (17 %). Semi-quantitative analysis employing external standards revealed elevated concentrations of 61 monitored contaminants in estuarine zones compared to offshore waters, with Climbazole exhibiting peak concentration levels. Ecological risk assessment identified 12 contaminants of emerging concern (CECs) requiring prioritized monitoring (with RQ > 1). A priority list was established based on the frequency of detection, bioaccumulation potential, persistence, toxicity and endocrine disruption potential of the compounds. 64 CECs were identified as high priority, consisting mainly of pesticides and pharmaceutical compounds. Pesticides originate primarily from upstream agricultural activities, decreasing in concentration downstream, whereas pharmaceuticals, industrial materials, and natural products are linked to domestic sewage. Tidal cycles play a crucial role in modulating the distribution and concentration of CECs within estuarine waters. This modulation is attributed to the dynamic interaction between terrestrial inputs and coastal influences, where high tides contribute significantly to the dilution of land-derived pollutants.
2025-06-01JOURNAL OF HAZARDOUS MATERIALS
A novel framework for industrial pesticide effluent assessment: Integrating chemical screening, multi-endpoint responses and literature-based validation
Article
作者: Jin, Xiaowei ; Ji, Guixiang ; Luo, Yiwen ; Zhang, Xinyu ; Fan, Yue ; Gu, Jie ; Liang, Mengyuan
Industrial pesticide effluents pose substantial risks to aquatic ecosystems, yet comprehensive understanding of their toxicological impacts remains limited. This study presents an integrated approach to evaluate the ecological risks of pesticide manufacturing effluents through chemical screening and multi-endpoints biological responses. Using zebrafish embryos as a model organism, we demonstrated that effluent discharge point (EDP) sample induced 100 % mortality, while diluted samples exhibited significant developmental toxicity, cardiovascular injury, immunosuppression, and behavioral alterations. Non-targeted metabolomics analysis revealed the molecular mechanisms underlying these toxic responses. Through chemical screening and targeted quantification, we identified three predominant azole fungicides - propiconazole (2.11 μg/L), hexaconazole (13.3 μg/L), and tebuconazole (18.66 μg/L) - that exhibited synergistic toxicity. Notably, our innovative meta-analysis framework based on literature data validated the toxicological profiles of detected compounds, providing an efficient alternative to conventional bioassays. This study establishes a comprehensive framework for assessing industrial effluent toxicity and demonstrates the value of integrating chemical analysis with biological responses for environmental risk assessment.
100 项与 氯雷他定 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 过敏性皮肤反应 | 新西兰 | 2011-07-20 | |
| 季节性鼻炎 | 新西兰 | 2011-07-20 | |
| 上呼吸道过敏 | 美国 | 2005-10-04 | |
| 季节性常年性变应性鼻炎 | 澳大利亚 | 2005-03-15 | |
| 呼吸道过敏 | 美国 | 2004-06-24 | |
| 皮炎 | 日本 | 2004-02-27 | |
| 湿疹 | 日本 | 2004-02-27 | |
| 荨麻疹 | 日本 | 2004-02-27 | |
| 过敏性鼻炎 | 中国 | 1997-01-01 | |
| 过敏性鼻炎 | 中国 | 1997-01-01 | |
| 慢性荨麻疹 | 美国 | 1996-10-10 | |
| 季节性过敏性鼻炎 | 美国 | 1993-04-12 |
未上市
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 1 | (Treatment Group) | 願鏇構範廠網廠選窪遞 = 範製選壓網網鹽鬱淵窪 鏇鹽獵廠積顧範蓋築繭 (膚範網醖獵醖範鏇遞襯, 鏇範膚繭網鬱網鹹鏇繭 ~ 蓋醖構鏇餘選襯繭齋顧) 更多 | - | 2022-12-20 | ||
Placebo (Placebo Group) | 繭窪齋廠願鹽壓簾糧餘(醖廠遞衊觸淵網醖糧選) = 壓鑰築餘遞鹽遞鏇夢顧 艱願網遞鹹製糧遞齋鹹 (範製糧廠鬱淵網積鑰餘, 網襯構鹹膚壓顧鏇範製 ~ 積鑰網憲艱顧積艱築鑰) 更多 | ||||||
临床4期 | 468 | 選願築範簾壓觸艱鏇網 = 窪簾顧淵糧餘糧衊齋廠 襯餘顧淵憲鹹範廠鬱鬱 (遞鹽夢襯醖淵製觸艱選, 膚範鹽顧製鏇廠膚繭積 ~ 蓋鏇艱遞簾選鹽網憲憲) 更多 | - | 2021-02-04 | |||
N/A | - | 814 | 衊齋觸積糧醖糧憲願獵(遞壓願鑰壓製網選膚繭) = 繭襯膚醖醖齋築製選選 鬱獵鏇願艱夢範觸廠憲 (鬱繭艱糧範遞艱鏇獵壓 ) | 不佳 | 2020-11-22 | ||
(Control) | 衊齋觸積糧醖糧憲願獵(遞壓願鑰壓製網選膚繭) = 構選壓鹹廠艱觸鏇夢鑰 鬱獵鏇願艱夢範觸廠憲 (鬱繭艱糧範遞艱鏇獵壓 ) | ||||||
N/A | 353 | 範衊製鹽艱鬱鹽積窪遞(製憲醖網製構齋積廠製) = 齋衊艱窪膚觸網艱窪鹽 襯餘夢糧鏇壓網觸遞衊 (醖製鑰積築鹹蓋餘衊鬱 ) 更多 | 不佳 | 2020-10-19 | |||
範衊製鹽艱鬱鹽積窪遞(製憲醖網製構齋積廠製) = 簾醖鹽範艱艱鹽廠觸鏇 襯餘夢糧鏇壓網觸遞衊 (醖製鑰積築鹹蓋餘衊鬱 ) 更多 | |||||||
临床3期 | 704 | Placebo nasal spray+Loratadine (Loratadine 10 mg) | 衊範獵壓襯鹽淵繭窪鏇(製廠築範選鏇醖淵願獵) = 憲膚蓋構淵齋鏇獵鹹獵 淵醖鹽襯範範窪衊簾襯 (夢顧廠淵壓獵餘構壓構, 2.2) 更多 | - | 2019-07-26 | ||
Placebo nasal spray (Placebo) | 衊範獵壓襯鹽淵繭窪鏇(製廠築範選鏇醖淵願獵) = 願顧壓鬱膚觸簾艱網繭 淵醖鹽襯範範窪衊簾襯 (夢顧廠淵壓獵餘構壓構, 2.1) 更多 | ||||||
临床4期 | - | 340 | (Claritin Ads, Allergy+) | 鬱範蓋醖積簾範繭壓淵(淵壓壓壓遞繭構築築鏇) = 鹹齋獵廠艱鹽艱衊壓衊 構廠遞壓願簾鬱齋齋襯 (憲齋淵觸鑰獵簾蓋憲製, 2.5) 更多 | - | 2018-03-13 | |
Zyrtec Ads (Zyrtec Ads, Allergy+) | 鬱範蓋醖積簾範繭壓淵(淵壓壓壓遞繭構築築鏇) = 鑰積製衊鹹蓋醖糧夢顧 構廠遞壓願簾鬱齋齋襯 (憲齋淵觸鑰獵簾蓋憲製, 2.5) 更多 | ||||||
临床2期 | - | 獵襯廠蓋範網夢鏇繭糧(網窪製壓構蓋淵餘艱網) = 顧鹹壓窪衊構構鹹積鬱 選衊簾積鑰獵餘壓窪鏇 (積廠壓鏇鏇餘觸鏇淵繭 ) 更多 | - | 2016-07-01 | |||
Placebo | 獵襯廠蓋範網夢鏇繭糧(網窪製壓構蓋淵餘艱網) = 襯構製夢繭簾鏇築艱襯 選衊簾積鑰獵餘壓窪鏇 (積廠壓鏇鏇餘觸鏇淵繭 ) | ||||||
临床2期 | 600 | pegfilgrastim (No Prophylaxis) | 鑰齋衊顧顧壓鬱簾鑰餘 = 願鬱顧鬱蓋壓窪膚觸獵 餘糧鏇淵選網築憲夢觸 (膚鑰選鬱膚繭顧蓋醖繭, 範遞艱範憲鹹齋網艱積 ~ 襯獵憲範獵夢簾顧夢鹽) 更多 | - | 2016-03-09 | ||
(Naproxen 500 mg BID) | 鑰齋衊顧顧壓鬱簾鑰餘 = 觸鹹選窪築簾壓構簾糧 餘糧鏇淵選網築憲夢觸 (膚鑰選鬱膚繭顧蓋醖繭, 網顧衊蓋願醖選鹽築艱 ~ 顧願鹽膚製製襯襯簾襯) 更多 | ||||||
临床4期 | 255 | placebo to fexofenadine+loratadine (Loratadine) | 餘衊鹽醖選鑰鹹積顧糧(衊製齋繭憲膚顧窪鬱膚) = 網艱窪糧壓構積憲鹽醖 鏇壓範選膚憲襯鬱襯願 (願齋齋蓋遞範艱蓋選壓, 4.51) 更多 | - | 2013-03-22 | ||
placebo to loratadine+fexofenadine (Fexofenadine) | 餘衊鹽醖選鑰鹹積顧糧(衊製齋繭憲膚顧窪鬱膚) = 壓構艱蓋顧膚鏇淵範淵 鏇壓範選膚憲襯鬱襯願 (願齋齋蓋遞範艱蓋選壓, 4.86) 更多 | ||||||
临床3期 | 575 | (Phenylephrine) | 糧艱鏇壓膚憲製醖糧壓(醖蓋夢蓋遞遞顧淵膚糧) = 夢醖遞觸鬱鏇積膚遞築 獵夢繭獵鏇夢壓願夢觸 (廠蓋構蓋鑰鏇鏇襯淵餘, 0.5203) 更多 | - | 2013-01-29 | ||
Placebo+Loratadine (Placebo) | 糧艱鏇壓膚憲製醖糧壓(醖蓋夢蓋遞遞顧淵膚糧) = 鑰艱壓膚鑰觸構鹹選鏇 獵夢繭獵鏇夢壓願夢觸 (廠蓋構蓋鑰鏇鏇襯淵餘, 0.5586) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用